FFM
VRDN icon

Fairmount Funds Management’s Viridian Therapeutics VRDN Stock Holding History

Fairmount Funds Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.5M Buy
5,090,928
+1,176,470
+30% +$19M 6.18% 7
2026
Q1 		$76.6M Hold
3,914,458
– – 5.53% 6
2025
Q4 		$122M Buy
3,914,458
+454,545
+13% +$12.5M 9.27% 4
2025
Q3 		$74.7M Hold
3,459,913
– – 6.72% 6
2025
Q2 		$48.4M Buy
3,459,913
+14,100
+0.4% +$191K 6.27% 9
2025
Q1 		$46.4M Hold
3,445,813
– – 7.21% 7
2024
Q4 		$66.1M Hold
3,445,813
– – 6.57% 7
2024
Q3 		$78.4M Buy
3,445,813
+1,600,000
+87% +$26.2M 6.36% 8
2024
Q2 		$24M Hold
1,845,813
– – 2.71% 11
2024
Q1 		$32.3M Buy
1,845,813
+476,190
+35% +$9.23M 3.52% 8
2023
Q4 		$29.8M Hold
1,369,623
– – 3.15% 8
2023
Q3 		$21M Hold
1,369,623
– – 2.53% 14
2023
Q2 		$32.6M Hold
1,369,623
– – 4.59% 7
2023
Q1 		$34.8M Hold
1,369,623
– – 5.99% 6
2022
Q4 		$40M Hold
1,369,623
– – 6.35% 5
2022
Q3 		$28.1M Buy
1,369,623
+425,531
+45% +$7.65M 4.94% 8
2022
Q2 		$10.9M Hold
944,092
– – 2.5% 15
2022
Q1 		$17.5M Hold
944,092
– – 4.13% 11
2021
Q4 		$18.7M Hold
944,092
– – 6.15% 6
2021
Q3 		$15.5M Buy
944,092
+909,000
+2,590% +$13.3M 5.65% 8
2021
Q2 		$642K Hold
35,092
– – 0.26% 18
2021
Q1 		$581K Hold
35,092
– – 0.24% 19
2020
Q4 		$554K Buy
+35,092
New +$529K 0.2% 18

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fairmount Funds Management's VRDN Position: Q2 2026 in Review

Fairmount Funds Management increased its Viridian Therapeutics (VRDN) stake by 30% in Q2 2026, buying an estimated $19M and bringing the position to 5,090,928 shares worth $93.5M. The position accounts for 6.18% of the portfolio, ranked #7.

Fairmount Funds Management first reported a position in VRDN in Q4 2020 and has held it in 23 quarters since. The position peaked at $122M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Fairmount Funds Management held 5,090,928 shares of Viridian Therapeutics worth $93.5M as of Q2 2026.
  • Fairmount Funds Management bought 1,176,470 Viridian Therapeutics shares in Q2 2026, an estimated $19M.
  • Viridian Therapeutics made up 6.18% of Fairmount Funds Management's portfolio in Q2 2026, its #7 holding.
  • Fairmount Funds Management first reported a position in Viridian Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Fairmount Funds Management's Viridian Therapeutics position peaked at $122M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.